Key Points
- Insider sale: Cintia Piccina sold 6,713 Autolus Therapeutics shares at an average of $2.34, reducing her holdings by 33.57% to 13,287 shares.
- Financial and stock performance: AUTL opened at $2.29, with a 12-month range of $1.17 to $2.58. In its latest quarter, the company reported a $0.15 loss per share—better than estimates—and revenue of $45.69 million, above expectations.
- Market outlook: Analysts maintain a “Moderate Buy” consensus with an average price target of $10.00, while institutional investors own 72.83% of the stock.
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) insider Cintia Piccina sold 6,713 shares of the company's stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $2.34, for a total value of $15,708.42. Following the completion of the sale, the insider owned 13,287 shares in the company, valued at $31,091.58. This represents a 33.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Autolus Therapeutics Stock Performance
AUTL opened at $2.29 on Friday. The company has a quick ratio of 4.40, a current ratio of 4.89 and a debt-to-equity ratio of 1.04. Autolus Therapeutics PLC Sponsored ADR has a 12-month low of $1.17 and a 12-month high of $2.58. The business has a 50 day moving average of $1.87 and a 200-day moving average of $1.66. The stock has a market cap of $609.51 million, a price-to-earnings ratio of -2.16 and a beta of 2.10.
Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.06. Autolus Therapeutics had a negative return on equity of 178.66% and a negative net margin of 238.66%.The business had revenue of $45.69 million for the quarter, compared to analyst estimates of $38.56 million. On average, equities research analysts expect that Autolus Therapeutics PLC Sponsored ADR will post -0.75 earnings per share for the current year.
Analyst Upgrades and Downgrades
Several brokerages have recently weighed in on AUTL. HC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a research report on Monday, August 3rd. Wall Street Zen raised shares of Autolus Therapeutics from a "sell" rating to a "hold" rating in a report on Sunday, August 16th. Finally, Weiss Ratings upgraded shares of Autolus Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, August 13th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $10.00.
View Our Latest Research Report on AUTL
Institutional Investors Weigh In On Autolus Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Syncona Portfolio Ltd bought a new stake in shares of Autolus Therapeutics in the second quarter valued at about $26,625,152. Schroder Investment Management Group increased its position in Autolus Therapeutics by 133.7% during the third quarter. Schroder Investment Management Group now owns 8,433,253 shares of the company's stock worth $13,409,000 after acquiring an additional 4,824,763 shares during the period. Mak Capital One LLC raised its stake in Autolus Therapeutics by 15.3% in the 4th quarter. Mak Capital One LLC now owns 30,005,343 shares of the company's stock worth $59,711,000 after purchasing an additional 3,987,727 shares in the last quarter. Armistice Capital LLC raised its stake in Autolus Therapeutics by 30.0% in the 3rd quarter. Armistice Capital LLC now owns 15,600,000 shares of the company's stock worth $25,428,000 after purchasing an additional 3,600,000 shares in the last quarter. Finally, Bank of America Corp DE increased its holdings in shares of Autolus Therapeutics by 108.1% during the third quarter. Bank of America Corp DE now owns 2,029,593 shares of the company's stock worth $3,308,000 after purchasing an additional 1,054,458 shares during the period. Institutional investors and hedge funds own 72.83% of the company's stock.
About Autolus Therapeutics
(
Get Free Report)
Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.
The company's leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
